Press Release: Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma

Press Release: Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma

Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and prolonged PFS compared to VRd alone With the first global approval in TE NDMM, Sarclisa is now approved in the EU across all lines of therapy, regardless of transplant eligibility Paris, Ju…

Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM

Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.

Sanofi Gains EU Approval for Sarclisa in First-Line Treatment of Transplant-Eligible Multiple Myeloma

Open the article to view the coverage from EuropaWire.eu